摘要
目的探讨低浓度(0.1 g·L^(-1))阿托品联合角膜塑形镜对青少年低中度近视患者治疗效果、泪膜功能及健康测量量表(SF-36)评分的影响。方法病例对照研究。选取98例青少年低中度近视患者为研究对象,按照随机数字表法分为观察组(49例)、对照组(49例);对照组患者仅使用角膜塑形镜治疗,观察组患者使用角膜塑形镜联合低浓度(0.1 g·L^(-1))阿托品滴眼液进行治疗。治疗前和治疗后3个月、6个月、12个月随访两组患者裸眼视力(UCVA)、角膜曲率、等效球镜度、角膜厚度、屈光度、眼压及泪膜功能。采用量表SF-36对两组患者治疗前及治疗后12个月的生活质量进行评价,统计两组患者的并发症发生情况。结果治疗后12个月,观察组患者UCVA、角膜曲率、等效球镜度、角膜厚度、屈光度分别为(0.16±0.10)logMAR、(40.04±0.69)D、(-2.28±0.51)D、(539±33)μm、(1.49±0.45)D,均明显优于对照组的UCVA(0.22±0.08)logMAR、角膜曲率(43.33±0.47)D、等效球镜度(-2.77±0.45)D、角膜厚度(545±34)μm、屈光度(-1.60±0.42)D(均为P<0.05)。治疗后12个月,观察组患者泪膜脂质层厚度、泪膜破裂时间分别为(55.42±5.07)nm、(5.14±1.72)s,均低于对照组的泪膜脂质层厚度(62.17±5.38)nm、泪膜破裂时间(6.29±2.08)s(均为P<0.05);治疗后12个月,观察组患者客观散射指数为1.99±0.28,高于对照组(1.24±0.35)(P<0.05);治疗后12个月,观察组患者SF-36量表各项评分均优于对照组(均为P<0.05)。两组患者治疗期间并发症发生率比较,差异均无统计学意义(均为P>0.05)。结论低浓度阿托品联合角膜塑形镜治疗青少年低中度近视效果显著,有助于改善患者视力及屈光度,提高患者生活质量,安全性相对较高,值得临床上推广应用。
Objective To study the effect of low-dose Atropine(0.1 g·L^(-1))combined with orthokeratology on correction effect,tear film function and the medical outcones study 36-item short-form health survey(SF-36)score.Methods The case-control studies were performed in 98 patients with low to moderate myopia,who were randomly selected and divided into the observation group(49 patients)and the control group(49 patients)according to the random number table methods.Patients in the control group were only treated with orthokeratology,while patients in the observation group were treated with low-dose(0.1 g·L^(-1))Atropine combined with orthokeratology.The uncorrected visual acuity(UCVA),corneal curvature,equivalent spherical power,corneal thickness,diopter,intraocular pressure and tear film function of the two groups were recorded at the baseline and 3 months,6 months and 12 months after treatment.Then the score of SF-36 scale was observed and compared in the two groups.The complications of the two groups were analyzed.Results After 12 months of treatment,the uncorrected visual acuity(UCVA),corneal curvature,equivalent spherical power,corneal thickness,diopter was(0.16±0.10)logMAR,(40.04±0.69)D,(-2.28±0.51)D,(539±33)μm,(1.49±0.45)D in the observation group,which were significantly better than those in the control group(0.22±0.08)logMAR,(43.33±0.47)D,(-2.77±0.45)D,(545±34)μm,(-1.60±0.42)D(all P<0.05).The lipid layer thickness and tear break-up time in the observation group were(55.42±5.07)nm and(5.14±1.72)s,which were lower than those of the control group(62.17±5.38)nm,(6.29±2.08)s(all P<0.05).Twelve months after treatment,the objective scatter index was 1.99±0.28 in the observation group,which was significantly better than that of the control group(1.24±0.35)(P<0.05).The scores of SF-36 in the observation group were better than those in the control group 12 months after treatment(all P<0.05).There was no significant difference in the incidence of complications between the two groups(P>0.05).Conclusion The e
作者
刘莉
邝国平
彭婧利
LIU Li;KUANG Guoping;PENG Jingli(Department of Ophthalmology,the First People’s Hospital of Chenzhou,Chenzhou 423000,Hunan Province,China)
出处
《眼科新进展》
CAS
北大核心
2021年第6期575-578,共4页
Recent Advances in Ophthalmology
